GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE (GASTRIC INHIBITORY POLYPEPTIDE; GIP)

作者: Christopher H.S. McIntosh , Scott Widenmaier , Su‐Jin Kim

DOI: 10.1016/S0083-6729(08)00615-8

关键词:

摘要: Glucose-dependent insulinotropic polypeptide (GIP; gastric inhibitory polypeptide) is a 42 amino acid hormone that produced by enteroendocrine K-cells and released into the circulation in response to nutrient stimulation. Both GIP glucagon-like peptide-1 (GLP-1) stimulate insulin secretion glucose-dependent manner are thus classified as incretins. The structure of mammalian well conserved both N-terminus central region molecule important for biological activity. Following secretion, metabolized endoprotease dipeptidyl peptidase IV (DPP-IV). In addition its activity, exerts number additional actions including promotion growth survival pancreatic beta-cell stimulation adipogenesis. brain, bone, cardiovascular system, gastrointestinal tract targets GIP. receptor member B-family G protein-coupled receptors activation results adenylyl cyclase Ca(2+)-independent phospholipase A(2) protein kinase (PK) A PKB. Mek1/2-Erk1/2 p38 MAP signaling pathways among downstream involved regulation function. also increases expression anti-apoptotic Bcl-2 decreases pro-apoptotic Bax, resulting reduced death. adipose tissue, interacts with increase lipoprotein lipase activity lipogenesis. There significant interest potential clinical applications analogs agonists antagonists have been developed preclinical studies.

参考文章(467)
Simon A. Hinke, Francis Lynn, Jan Ehses, Nathalie Pamir, Susanne Manhart, Kerstin Kühn-Wache, Fred Rosche, Hans-Ulrich Demuth, Raymond A. Pederson, Christopher H.S. McIntosh, Glucose-dependent Insulinotropic Polypeptide (GIP): Development of DP IV-Resistant Analogues with Therapeutic Potential Advances in Experimental Medicine and Biology. ,vol. 524, pp. 293- 301 ,(2004) , 10.1007/0-306-47920-6_35
Raymond A. Pederson, Christopher H.S. McIntosh, GIP (Gastric Inhibitory Polypeptide) Encyclopedia of Endocrine Diseases. pp. 202- 207 ,(2004) , 10.1016/B0-12-475570-4/00528-X
Jens F. Rehfeld, Clinical endocrinology and metabolism. Cholecystokinin. Best Practice & Research Clinical Endocrinology & Metabolism. ,vol. 18, pp. 569- 586 ,(2004) , 10.1016/J.BEEM.2004.07.002
J. W. Wright, J. A. Knapper, M. C. Murphy, B. J. Gould, Christine M. Williams, S. G. Isherwood, S Sethi, Postprandial lipid and hormone responses to meals of varying fat contents: modulatory role of lipoprotein lipase? European Journal of Clinical Nutrition. ,vol. 49, pp. 578- ,(1995)
Christopher, H.S. McIntosh, Dipeptidyl peptidase iv inhibitors and diabetes therapy Frontiers in Bioscience. ,vol. 13, pp. 1753- ,(2008) , 10.2741/2797
John C. Brown, Role of Gastric Inhibitory Polypeptide in Regulation of Insulin Release Frontiers of Hormone Research. ,vol. 16, pp. 157- 166 ,(1987) , 10.1159/000414306
Juris J Meier, Michael A Nauck, Bartholomaeus Kask, Jens J Holst, Carolyn F Deacon, Wolfgang E Schmidt, Baptist Gallwitz, None, Influence of gastric inhibitory polypeptide on pentagastrin-stimulated gastric acid secretion in patients with type 2 diabetes and healthy controls. World Journal of Gastroenterology. ,vol. 12, pp. 1874- 1880 ,(2006) , 10.3748/WJG.V12.I12.1874
Máire E. Doyle, Josephine M. Egan, Mechanisms of action of glucagon-like peptide 1 in the pancreas Pharmacology & Therapeutics. ,vol. 113, pp. 546- 593 ,(2007) , 10.1016/J.PHARMTHERA.2006.11.007
Brigitte AMIRANOFF, Alain COUVINEAU, Nicole VAUCLIN-JACQUES, Marc LABURTHE, Gastric inhibitory polypeptide receptor in hamster pancreatic beta cells. Direct cross-linking, solubilization and characterization as a glycoprotein. FEBS Journal. ,vol. 159, pp. 353- 358 ,(1986) , 10.1111/J.1432-1033.1986.TB09875.X
Yasushige Kashima, Takashi Miki, Tadao Shibasaki, Nobuaki Ozaki, Masaru Miyazaki, Hideki Yano, Susumu Seino, Critical role of cAMP-GEFII--Rim2 complex in incretin-potentiated insulin secretion. Journal of Biological Chemistry. ,vol. 276, pp. 46046- 46053 ,(2001) , 10.1074/JBC.M108378200